<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04641910</url>
  </required_header>
  <id_info>
    <org_study_id>RC20_0406</org_study_id>
    <nct_id>NCT04641910</nct_id>
  </id_info>
  <brief_title>Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid Leukemia</brief_title>
  <acronym>FLAMVAL</acronym>
  <official_title>Validation Study of a New Cytokine-based Dynamic Stratification Based on FLt3 Ligand Plasma Concentration Kinetic Profile and IL-6 Concentration During Induction of Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have recently demonstrated the strong impact in terms of survivals of&#xD;
      Fms-like tyrosine kinase 3 ligand (FL) levels evaluated during intensive induction in acute&#xD;
      myeloid leukemia (AML) patients. Indeed, three FL kinetic profiles were delineated: i)&#xD;
      sustained increase of FL concentrations between day (D) 1 and D22 (FLI group, n=26,&#xD;
      good-risk), ii) increase from D1 to D15, then decrease at D22 (FLD group, n=22,&#xD;
      intermediate-risk) and iii) stagnation of low levels (&lt;1000 pg/mL, FLL group, n=14,&#xD;
      high-risk). However, with longer follow-up, the investigators have observed that FLI and FLD&#xD;
      shared similar outcomes while FLL sub-group kept a very bad prognostic.&#xD;
&#xD;
      Because serum samples from this previous study (called the FLAM/FLAL study) had been&#xD;
      frozen-stored, the investigators were able to conduct an ancillary study assessing the&#xD;
      potential impact of the kinetics of 6 other cytokines: TNFalpha, stem-cell factor, IL-1beta,&#xD;
      IL-6, IL-10 and granulocyte-monocyte colony-stimulating factor (GM-CSF).. Only Il-6 level at&#xD;
      D22 (&lt; or &gt;15.5 pg/mL) was associated with outcome allowing to distinguish between higher and&#xD;
      lower survivals within the combined FLI/FLD sub-group.&#xD;
&#xD;
      A new prognostic risk-stratification can thus be proposed as follows: FLI/FLD with IL-6 &lt;15.5&#xD;
      pg/mL (favorable), FLI/FLD with IL-6 &gt;15.5 pg/mL (intermediate) and FLL (high-risk).&#xD;
&#xD;
      The aim of this new FLAMVAL study is to validate prospectively in a larger and independent&#xD;
      cohort this prognostic risk-stratification i.e. that kinetic profile of FLT3L plasma level&#xD;
      from D1 to D22 and Il6 plasma level at day 22 during induction of AML patients are predictive&#xD;
      of overall and disease free survivals.&#xD;
&#xD;
      For that purpose, 201 newly diagnosed AML patients treated intensively in the 25 centres of&#xD;
      the French Innovative Leukemia Organisation (FILO) will be included in the FLAMVAL study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">June 8, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 8, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Confirm that the combination of the kinetic profile of FLT3L plasma levels and the IL-6 plasma level at day22 during induction in AML patients is predictive of overall survival.</measure>
    <time_frame>2 years</time_frame>
    <description>time from day 1 of induction to the date of death or of last follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirm that the combination of the kinetic profile of FLT3L plasma levels and the IL-6 plasma level at day22 during induction in AML patients is predictive of overall survival.</measure>
    <time_frame>2 years</time_frame>
    <description>serum FL concentration is measured at day 1, 8, 15 et 22 of induction by ELISA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirm that the combination of the kinetic profile of FLT3L plasma levels and the IL-6 plasma level at day22 during induction in AML patients is predictive of overall survival.</measure>
    <time_frame>2 years</time_frame>
    <description>level of IL-6 at day 22 has been also shown to have prognostic impact for FLD/FLI patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirm that the new FL/IL6 risk-model predicts leukemia free survival in first-line AML patients.</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free survival (PFS): time from day 1 of induction to refractory disease or relapse censored at the date of death or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the prognostic impact of the new FL/IL6 risk-model with the impact of other parameters known to predict outcome in AML</measure>
    <time_frame>2 years</time_frame>
    <description>Refractory status after induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study the impact of the new FL/IL6 risk-model in FLT3 ITD or TKD patients receiving or not FLT3 inhibitors</measure>
    <time_frame>2 years</time_frame>
    <description>cytokines plasma levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Immune reconstitution during induction</measure>
    <time_frame>2 years</time_frame>
    <description>By flow cytometry</description>
  </secondary_outcome>
  <enrollment type="Anticipated">201</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples at day 1, day 8, day 15, day 22, day 30&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any newly diagnosed AML patients treated intensively in centres belonging to the FILO group&#xD;
        will be eligible for the FLAMVAL study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18 years old&#xD;
&#xD;
          -  Confirmed diagnosis of AML according to World Health Organization (WHO) 2016&#xD;
             classification (Arber et al., 2016)&#xD;
&#xD;
          -  Non previously treated AML (first-line therapy)&#xD;
&#xD;
          -  Patients eligible to standard 3+7 induction chemotherapy with a minimum of 3 days of&#xD;
             daunorubicin at 45mg/m2/day or a minimum of 5 days of idarubicin at 8mg/m2/day and a&#xD;
             minimum of 7 days of cytarabin at 100mg/m2/day&#xD;
&#xD;
          -  Patients receiving any &quot;third drug&quot; combined to the &quot;3+7&quot; scheme, i.e. lomustine,&#xD;
             corticotherapy, elthrombopag, gemtuzumab-ozogamycin, any FLT3 inhibitors… are eligible&#xD;
&#xD;
          -  Patients receiving CPX-351 (Vyxeos ®) are eligible&#xD;
&#xD;
          -  Patients requiring leukapheresis are eligible&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with Acute Promyelocytic Leukemia (AML-3)&#xD;
&#xD;
          -  Adults under guardianship, subjects under protection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre Peterlin</last_name>
    <phone>0240087418</phone>
    <email>pierre.peterlin@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Strasbourg University Hospital</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paoli-Calmette Institute</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhône</state>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Besançon University Hospital</name>
      <address>
        <city>Besançon</city>
        <state>Doubs</state>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brest University Hospital</name>
      <address>
        <city>Brest</city>
        <state>Finistère</state>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nîmes University Hospital</name>
      <address>
        <city>Nîmes</city>
        <state>Gard</state>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mulhouse Hospital Center</name>
      <address>
        <city>Mulhouse</city>
        <state>Haut-Rhin</state>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toulouse University Cancer Institute</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Béziers Hospital Center</name>
      <address>
        <city>Béziers</city>
        <state>Hérault</state>
        <zip>34500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <state>Ille-et-Vilaine</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tours University Hospital</name>
      <address>
        <city>Tours</city>
        <state>Indre-et-Loire</state>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <state>Isère</state>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Peterlin</last_name>
      <phone>0240087418</phone>
      <email>pierre.peterlin@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Etienne University Hospital</name>
      <address>
        <city>Saint-Étienne</city>
        <state>Loire</state>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <state>Maine-et-Loire</state>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Reims University Hospital</name>
      <address>
        <city>Reims</city>
        <state>Marne</state>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nancy University Hospital</name>
      <address>
        <city>Nancy</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mercy Regional Hospital</name>
      <address>
        <city>Metz</city>
        <state>Moselle</state>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Puy-de-Dôme</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Basque coast hospital center</name>
      <address>
        <city>Bayonne</city>
        <state>Pyrénées-Atlantiques</state>
        <zip>64102</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint-Jean Hospital Center</name>
      <address>
        <city>Perpignan</city>
        <state>Pyrénées-Orientales</state>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lyon University Hospital</name>
      <address>
        <city>Lyon</city>
        <state>Rhône</state>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AP-HP Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Poitiers University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

